Skip to main content

Table 2 The univariate analysis for IPSS increment. The univariate analysis of wheather t-IPSS increased by ten or over ten points during 91–180 days after ISBT. Similary, o-IPSS and i-IPSS increment of five or over five points during the same time period was analyzed

From: After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer

p value

Factor

 

t-IPSS+10

o-IPSS+5

i-IPSS+5

Age

<66.17 vs >66.17

0.838

0.959

0.253

Prostate volume

<36.7 ml vs >36.7 ml

0.681

0.457

0.750

Risk group

intermediate vs high

0.820

0.540

0.318

Initial PSA

<11.84 vs >11.84

1.000

0.609

0.124

Baseline t-IPSS

<7.67 vs >7.67

0.217

0.400

0.253

ADT

yes vs no

1.000

0.505

0.472

Brachytherapy technique

LDR-ISBT vs HDR-ISBT

0.066

0.193

0.010*

D50 % of urethra

<95.65 Gy vs >95.65 Gy

0.024*

0.101

0.031*

D50 % of base of urethra

<95.70 Gy vs >95.70 Gy

0.152

0.397

0.031*

V90 of urethra

<85.32 % vs >85.32 %

0.152

0.397

0.031*

V90 of base of urethra

<75.01 % vs >75.01 %

0.152

0.397

0.031*

V100 of urethra

<17.05 % vs >17.05 %

0.217

0.535

0.005*

  1. Abbreviations: ADT androgen deprivation therapy, IPSS international Prostate Symptom Score, t-IPSS total score of IPSS, o-IPSS + 5 total score of IPSS about obstructive symptom, i-IPSS + 5 total score of IPSS about irritative symptom, Dx% minimum dose delivered to x% of the organ volume, Vx proportion of volume receiving x Gy. The Gy indicates the dose which was converted into the EQD2
  2. The * indicates a variable that has a significant difference